Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Epithelial–Mesenchymal Transition: A Major Pathogenic Driver in Idiopathic Pulmonary Fibrosis?
Francesco Salton, Barbara Ruaro, Paola Confalonieri, et al.
Medicina (2020) Vol. 56, Iss. 11, pp. 608-608
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

The History and Mystery of Alveolar Epithelial Type II Cells: Focus on Their Physiologic and Pathologic Role in Lung
Barbara Ruaro, Francesco Salton, Luca Braga, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2566-2566
Open Access | Times Cited: 220
Regeneration or Repair? The Role of Alveolar Epithelial Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF)
Paola Confalonieri, Maria Concetta Volpe, Justin Jacob, et al.
Cells (2022) Vol. 11, Iss. 13, pp. 2095-2095
Open Access | Times Cited: 104
Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
Maria Chianese, Gianluca Screm, Francesco Salton, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 6, pp. 709-709
Open Access | Times Cited: 21
Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis
Elisa Baratella, Barbara Ruaro, Fabiola Giudici, et al.
Diagnostics (2021) Vol. 11, Iss. 5, pp. 762-762
Open Access | Times Cited: 56
Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis
Hongbo Ma, Xuyi Wu, Yi Li, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 56
Immunotherapy of inflammatory bowel disease (IBD) through mesenchymal stem cells
Huldani Huldani, Ria Margiana, Fawad Ahmad, et al.
International Immunopharmacology (2022) Vol. 107, pp. 108698-108698
Closed Access | Times Cited: 40
The uPA/uPAR System Orchestrates the Inflammatory Response, Vascular Homeostasis, and Immune System in Fibrosis Progression
Yosuke Kanno
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1796-1796
Open Access | Times Cited: 29
Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study
Barbara Ruaro, Andrea Salotti, Nicolò Reccardini, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 1, pp. 119-119
Open Access | Times Cited: 12
Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis
Hongbo Ma, Shengming Liu, Shanrui Li, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 35
The Role of Lung Microbiome in Fibrotic Interstitial Lung Disease—A Systematic Review
Ruxandra Puiu, Nicoleta Ștefania Motoc, Sergiu Lucaciu, et al.
Biomolecules (2024) Vol. 14, Iss. 3, pp. 247-247
Open Access | Times Cited: 6
The Regenerative Power of Stem Cells: Treating Bleomycin-Induced Lung Fibrosis
Amrita Vats, Pankaj Chaturvedi
Stem Cells and Cloning Advances and Applications (2023) Vol. Volume 16, pp. 43-59
Open Access | Times Cited: 13
Role of BAL and Serum Krebs von den Lungen-6 (KL-6) in Patients with Pulmonary Fibrosis
Piera Soccio, Giorgia Moriondo, Miriana d’Alessandro, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 269-269
Open Access | Times Cited: 4
Traditional Chinese Medicine Ion Introduction Therapy Reduces the Incidence of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Prospective Cohort Study
Yan Wang, B. Xu, Jiajia Wang, et al.
International Journal of General Medicine (2025) Vol. Volume 18, pp. 21-32
Open Access
Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease
Kunrong Yu, Wanying Li, Wenjie Long, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Use quercetin for pulmonary fibrosis: a preclinical systematic review and meta-analysis
Xuanyu Wu, Xiang Xiao, Yuchen Su, et al.
Inflammopharmacology (2025)
Closed Access
Huangqi Guizhi Wuwu Decoction Improves Arthritis and Pathological Damage of Heart and Lung in TNF-Tg Mice
Yi Wang, Tao Chen, Can Yang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 17
Circulating inflammatory cytokines and risk of idiopathic pulmonary fibrosis: a Mendelian randomization study
Qinyao Jia, Yan‐Mei Lei, Shaoping Chen, et al.
BMC Pulmonary Medicine (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Structural Modification and Optimisation of Hyperoside Oriented to Inhibit TGF-β-Induced EMT Activity in Alveolar Epithelial Cells
Zi-ye Gao, Meng-Zhen Xu, Chuanguo Liu, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 584-584
Open Access | Times Cited: 3
Using Routinely Collected Electronic Healthcare Record Data to Investigate Fibrotic Multimorbidity in England
Georgie M Massen, Hannah Whittaker, Sarah Cook, et al.
Clinical Epidemiology (2024) Vol. Volume 16, pp. 433-443
Open Access | Times Cited: 3
Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-World Observation on Efficacy and Safety, Focus on Patients Undergoing Antithrombotic and Anticoagulant
Nicolò Reccardini, Maria Chernovsky, Francesco Salton, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 930-930
Open Access | Times Cited: 3
Promises and Challenges of Cell-Based Therapies to Promote Lung Regeneration in Idiopathic Pulmonary Fibrosis
Alejandro Egea-Zorrilla, Laura Vera, Borja Sáez, et al.
Cells (2022) Vol. 11, Iss. 16, pp. 2595-2595
Open Access | Times Cited: 13
Inhibitory Effects of 3-Cyclopropylmethoxy-4-(difluoromethoxy) Benzoic Acid on TGF-β1-Induced Epithelial–Mesenchymal Transformation of In Vitro and Bleomycin-Induced Pulmonary Fibrosis In Vivo
Tian‐Xiao Sun, Haihua Li, Yan Zhang, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6172-6172
Open Access | Times Cited: 7
Reversal of Pulmonary Fibrosis: Human Umbilical Mesenchymal Stem Cells from Wharton’s Jelly versus Human-Adipose-Derived Mesenchymal Stem Cells
Kuo‐An Chu, Chang‐Ching Yeh, Chun-Hsiang Hsu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 6948-6948
Open Access | Times Cited: 7
Correlation between Potential Risk Factors and Pulmonary Embolism in Sarcoidosis Patients Timely Treated
Barbara Ruaro, Paola Confalonieri, Mario Santagiuliana, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 11, pp. 2462-2462
Open Access | Times Cited: 16
Effect of Baricitinib on the epithelial-mesenchymal transition of alveolar epithelial cells induced by IL-6
Yiping Liu, Ming Hu, Guanzhi Fan, et al.
International Immunopharmacology (2022) Vol. 110, pp. 109044-109044
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top